Skip to main content
OpenTrials

Clinical trial condition

Platinum-resistant Ovarian Cancer

Explore clinical trials studying Platinum-resistant Ovarian Cancer. Study availability and eligibility vary by location and protocol.

25 public trials 13 recruiting studies
Refine in advanced search Browse all conditions

Platinum-resistant Ovarian Cancer trial results

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Conditions
Adnexal Diseases, DNA Virus Infections, Endocrine Gland Neoplasms, +26 more
Locations
  • The University of South Alabama, Mitchell Cancer Institute Mobile, Alabama, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health - Moores Cancer Center La Jolla, California, United States
View all 32 locations
View Trial Details
Recruiting

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

NCT07226427

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +13 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • Yale University New Haven, Connecticut, United States
  • Florida Cancer Specialists & Research Institute Sarasota, Florida, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View all 15 locations
View Trial Details
Recruiting

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT06515613

Conditions
Endocrine Gland Neoplasms, Endocrine System Diseases, Endometrial Cancer, +20 more
Locations
  • University of Arkansas Winthrop P. Rockefeller Cancer Institute Little Rock, Arkansas, United States
  • Precision NextGen Oncology & Research Center Beverly Hills, California, United States
  • SCRI at Denver Health Denver, Colorado, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 14 locations
View Trial Details
Recruiting

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

NCT06730347

Conditions
Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Ovary, +20 more
Locations
  • UCLA Los Angeles, California, United States
  • Ochsner MD Anderson Cancer Center New Orleans, Louisiana, United States
  • START Midwest Grand Rapids, Michigan, United States
  • West Penn Allegheny Health Pittsburgh, Pennsylvania, United States
View all 16 locations
View Trial Details
Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT06586957

Conditions
Adnexal Diseases, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, +62 more
Locations
  • University of Arkansas Medical School Little Rock, Arkansas, United States
  • University of California - Los Angeles Los Angeles, California, United States
  • UCSF San Francisco, California, United States
  • SCRI at HealthOne Denver, Colorado, United States
View all 19 locations
View Trial Details
Recruiting

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

NCT06547840

Conditions
Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Diseases, +20 more
Locations
  • Bristol Haematology and Oncology Centre Bristol, United Kingdom
  • Edinburgh Cancer Research Centre Edinburgh, United Kingdom
  • Leeds Teaching Hospitals NHS Trust Leeds, United Kingdom
  • Cambridge University - Addenbrooke's Hospital London, United Kingdom
View Trial Details

Related conditions